{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:36:51Z","timestamp":1790692611186,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2017,11]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Patch testing following a standardized protocol is reliable for identifying the culprit drug in cutaneous adverse drug reactions (CADR<\/jats:styled-content>s). However, these patch tests (PTs<\/jats:styled-content>) require pharmaceutical material and staff, which are not always easily available.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To evaluate an extemporaneous PT<\/jats:styled-content> method in CADRs<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>We retrospectively analysed data for all patients referred to our department between M<\/jats:styled-content>arch 2009 and J<\/jats:styled-content>une 2013 for patch testing after a non\u2010immediate CADR<\/jats:styled-content>. The patients who supplied their own suspected drugs were tested both with extemporaneous PTs<\/jats:styled-content> and with conventional PT<\/jats:styled-content>s. Extemporaneous PTs<\/jats:styled-content> involved a nurse crushing and diluting the drug in pet. in a ratio of approximately one\u2010third to two\u2010thirds. Standardized PTs<\/jats:styled-content> were performed according to guidelines, with commercial drugs diluted to 30% or with active ingredients diluted to 10%. We analysed the data for the two PT<\/jats:styled-content> methods in terms of the number of positive test reactions, drugs tested, and type of CADR<\/jats:styled-content> for patients in whom the two PT<\/jats:styled-content> methods were used.<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 75 of 156 patients underwent the two PT<\/jats:styled-content> procedures, including 91 double tests. Overall, 21 tests gave positive reactions with the two methods, and 69 other tests gave negative results with the two methods.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Our series yielded results similar to those of published series concerning the types of CADR<\/jats:styled-content> and the drugs responsible. Our results suggest that, for CADR<\/jats:styled-content>s, if a patient supplies a suspected drug but if the pharmaceutical material and staff are not available for conventional PT<\/jats:styled-content>s, extemporaneous PT<\/jats:styled-content>s performed by the nurse with the commercial drug used by the patient can be useful and reliable.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cod.12842","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T08:26:55Z","timestamp":1500625615000},"page":"297-302","source":"Crossref","is-referenced-by-count":31,"title":["Patch testing in non\u2010immediate cutaneous adverse drug reactions: value of extemporaneous patch tests"],"prefix":"10.1111","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-1241","authenticated-orcid":false,"given":"Haudrey","family":"Assier","sequence":"first","affiliation":[{"name":"Department of Dermatology, Referral Centre for Toxic Bullous Diseases AP\u2010HP, H\u00f4pital Henri\u2010Mondor, UPEC 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Valeyrie\u2010Allanore","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Referral Centre for Toxic Bullous Diseases AP\u2010HP, H\u00f4pital Henri\u2010Mondor, UPEC 94010 Cr\u00e9teil France"},{"name":"EA 7379 EpiDermE, UPEC 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendeline","family":"Gener","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Referral Centre for Toxic Bullous Diseases AP\u2010HP, H\u00f4pital Henri\u2010Mondor, UPEC 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Verlinde Carvalh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy AP\u2010HP, H\u00f4pital Henri\u2010Mondor 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chosidow","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Referral Centre for Toxic Bullous Diseases AP\u2010HP, H\u00f4pital Henri\u2010Mondor, UPEC 94010 Cr\u00e9teil France"},{"name":"EA 7379 EpiDermE, UPEC 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Referral Centre for Toxic Bullous Diseases AP\u2010HP, H\u00f4pital Henri\u2010Mondor, UPEC 94010 Cr\u00e9teil France"},{"name":"EA 7379 EpiDermE, UPEC 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90918-3"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30378-6"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01578.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06429.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.450601.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0560.2001.028003113.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12432"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb01593.x"},{"key":"e_1_2_6_13_1","first-page":"385","article-title":"Toxidermies exanth\u00e9matiques et pustuleuses. A propos de 6 cas. Revue de la litt\u00e9rature","volume":"1","author":"Plantin P","year":"1988","journal-title":"Rech Dermatol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2340\/0001555558545547","article-title":"Pulsating fixed drug eruption to tetracycline","volume":"58","author":"Parish L C","year":"1978","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1990.tb01631.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1981.tb00038.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02364.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02313.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12125"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2010.09.008"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01659.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2147"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.450502.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00452.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12269"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1995.tb02060.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02255.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1992.tb03291.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.02161.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10164"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1108"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2003.00065.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08516.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00105.x"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcod.12842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.12842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T12:25:48Z","timestamp":1695990348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cod.12842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/cod.12842"],"URL":"https:\/\/doi.org\/10.1111\/cod.12842","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}